For the first few years of the 2020s, Novo Nordisk (NVO) has been treated like it could do no wrong - the poster child of the GLP-1 boom and one of the most crowded trades on the planet.
But markets have a way of humbling consensus.
Shares dropped hard after disappointing results from its next-generation obesity drug CagriSema, which showed weaker weight-loss efficacy than Eli Lilly’s (LLY) rival therapy in a major late-stage trial.
The selloff wiped out a massive chunk of momentum and forced investors to confront an uncomfortable reality: leadership in biotech can change fast.
And when it does, capital doesn’t disappear - it rotates.
The Market Is Finally Pricing Reality
For months, investors priced Novo as if dominance in obesity drugs was guaranteed for the next decade. That was always an aggressive assumption in a space where innovation cycles move fast and competitive advantages don’t last forever.
Now we’re seeing the repricing.
Because this isn’t just about one trial missing expectations - it’s about the realization that the GLP-1 market is becoming a full-scale arms race.
And in arms races, the winners aren’t always the incumbents.
Big Pharma Will Do What Big Pharma Always Does
When pipeline pressure rises, large pharmaceutical companies don’t sit still.
They buy innovation.
That’s exactly what could happen if competitive gaps widen - and it’s why smaller clinical-stage obesity drug developers are suddenly back on investors’ radar.
This is the phase of a biotech cycle where asymmetric opportunities start to emerge - before Wall Street fully reprices the next generation of leaders.
The NXT Wave Names You Should be Watching
If the GLP-1 trade is entering phase two, several smaller players could become increasingly important:
Viking Therapeutics (VKTX) — Developing a dual GLP-1/GIP therapy with strong early data and growing attention as a potential competitor or acquisition target. Up 10% today.
Viking Therapeutics (VKTX)
Structure Therapeutics (GPCR) — Focused on oral incretin therapies, one of the most strategically valuable areas in metabolic medicine. Up 0.5% today.
Structure Therapeutics (GPCR)
Altimmune (ALT) — A high-risk, high-reward metabolic drug developer often mentioned as a possible partner candidate.
Altimmune (ALT)
Zealand Pharma (ZLDPF) — Working on amylin-based approaches that could complement or compete with existing GLP-1 therapies.
Zealand Pharma (ZLDPF)
These aren’t low-risk names - but that’s exactly the point.
Early-stage innovation is where the biggest upside historically lives when a megatrend matures.
My Take
The GLP-1 story isn’t ending.
But the easy money phase probably is.
The next phase will be more volatile, more competitive, and far more selective - and that’s where real opportunities tend to emerge for investors willing to look beyond the obvious winners.
Novo’s stumble isn’t a reason to abandon the theme.
It’s a reminder that megatrends evolve - and when they do, leadership shifts.
And right now, that shift may just be getting started.
Here’s to your future,
Matt McCall
Founder, NXT Wave Research
